Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session XXII: Colorectal Cancer: Metastatic Disease

Clinical efficacy and single cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

Date

02 Jul 2022

Session

Session XXII: Colorectal Cancer: Metastatic Disease

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Ryan Corcoran, United States

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.